Background: Neutropenia is one of the most important dose-limiting toxicities of docetaxel. Docetaxel is metabolized by cytochrome P450 3A4 (CYP3A4). Clarithromycin, a potent inhibitor of CYP3A4, is occasionally used in combination with docetaxel. The aim of this study was to evaluate whether the risk of severe neutropenia induced by docetaxel was increased by concomitant administration of clarithromycin. Methods: Patients with advanced lung cancer receiving docetaxel were identified from an electronic medical record system and divided into 2 groups: concomitant administration of clarithromycin and no concomitant administration of clarithromycin. The proportion of patients experiencing grade 4 neutropenia between the 2 groups was compared. Potential risk factors associated with grade 4 neutropenia were also examined using univariate and multivariate logistic regression analyses. Results: One hundred and fifty-eight patients were analysed. Grade 4 neutropenia was more frequently detected in the patients receiving clarithromycin than in those not receiving the drug (63.2 vs. 35.3%; p = 0.025). Multivariate analysis showed that co-administration of clarithromycin [odds ratio (OR) 4.98; p = 0.004], pre-treatment absolute neutrophil count (OR 2.62; p = 0.011) and female gender (OR 2.75; p = 0.029) resulted in an increase in the incidence of grade 4 neutropenia. Conclusions: This study shows that concomitant administration of clarithromycin potentiated docetaxel-induced myelosuppression.

Keywords:
Chemotherapy-induced neutropenia, Docetaxel, Clarithromycin, Cytochrome P450 3A4
1.
Scripture CD, Figg WD: Drug interactions in cancer therapy. Nat Rev Cancer 2006;6:546-558.
2.
Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA: Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289:1652-1658.
3.
Reimche L, Forster AJ, van Walraven C: Incidence and contributors to potential drug-drug interactions in hospitalized patients. J Clin Pharmacol 2011;51:1043-1050.
4.
Crawford J, Dale DC, Lyman GH: Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228-237.
5.
Clarke SJ, Rivory LP: Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114.
6.
Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, et al: Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002;20:3683-3690.
7.
Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N: Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 2000;18:2301-2308.
8.
British Thoracic Society Standards of Care Committee: BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001;56(suppl 4):IV1-IV64.
9.
Keicho N, Kudoh S: Diffuse panbronchiolitis: role of macrolides in therapy. Am J Respir Med 2002;1:119-131.
10.
Azuma A, Kudoh S: Diffuse panbronchiolitis in East Asia. Respirology 2006;11:249-261.
11.
Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, et al: The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-832.
12.
Zhou SF: Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9:310-322.
13.
Masaoka T: Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 2004;39(suppl 1):S49-S52.
14.
Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, et al: Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16:187-196.
15.
Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, et al: Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004;75:448-454.
16.
Westphal JF: Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000;50:285-295.
17.
Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, et al: Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44:279-304.
18.
Rengelshausen J, Göggelmann C, Burhenne J, Riedel KD, Ludwig J, Weiss J, et al: Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol 2003;56:32-38.
19.
Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ: P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999;59:3944-3948.
20.
Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, et al: Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005;6:669-677.
21.
Kishida Y, Kawahara M, Teramukai S, Kubota K, Komuta K, Minato K, et al: Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03. Br J Cancer 2009;101:1537-1542.
22.
Cameron DA, Massie C, Kerr G, Leonard RC: Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003;89:1837-1842.
23.
Watanabe H, Ikesue H, Oshiro M, Nagata K, Mishima K, Takada A, et al: Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer. Chemotherapy 2012;58:419-425.
24.
Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:4302-4311.
25.
Lyman GH, Lyman CH, Agboola O: Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427-437.
26.
Yano R, Tani D, Watanabe K, Tsukamoto H, Igarashi T, Nakamura T, et al: Evaluation of potential interaction between vinorelbine and clarithromycin. Ann Pharmacother 2009;43:453-458.
27.
Jenkins P, Scaife J, Freeman S: Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer. Ann Oncol 2012;23:1766-1771.
28.
Nicolson TJ, Mellor HR, Roberts RR: Gender differences in drug toxicity. Trends Pharmacol Sci 2010;31:108-114.
29.
Greenblatt DJ, von Moltke LL: Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol 2008;48:1350-1355.
30.
Chen M, Ma L, Drusano GL, Bertino JS Jr, Nafziger AN: Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther 2006;80:531-538.
31.
Wailoo A, Sutton A, Morgan A: The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis. Br J Cancer 2009;100:436-441.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.